Adverse reactions reported in ≥ 1% of patients in clinical trials at the recommended regime [1.5 mg/ m2, 24 hour infusion every 3 weeks (24-h q3wk)] Very Common Blood creatine phosphokinase increased, Blood creatinine increased, Blood albumin decreased Common Weight decreased